Cancer Treatments Linked to Aggravated Insomnia
the Cancer Therapy Advisor take:
Insomnia symptoms become intensified by cancer treatments and their side effects, according to a study published online in the journal Cancer.
In a longitudinal study involving 465 patients with breast cancer and 263 patients with prostate cancer, Insomnia Severity Index (ISI) and somatic symptoms were assessed at baseline and 2, 6, 10, 14, and 18 months later.
Results showed that patients with breast cancer who underwent radiotherapy and chemotherapy experienced an increased insomnia severity, but those who underwent hormone therapy did not. In patients with prostate cancer, androgen deprivation therapy was also associated with increased insomnia.
A variety of somatic symptoms were found to significantly mediate the effects of chemotherapy and radiotherapy on insomnia in patients with breast cancer.
Furthermore, night sweats were determined to have a significant mediating role for hormone therapy in patients with breast cancer and patients with prostate cancer.
The study suggests that side effects of cancer treatments be more closely monitored and managed in order to prevent the aggravation of insomnia symptoms in patients.
Insomnia symptoms become intensified by cancer treatments and their side effects.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC